DEZIMA PHARMA
Dezima Pharma B.V. develops protein-based compounds for treatment of cardiovascular disease related to dyslipidemia. The company was founded in 2012 and is based in Naarden, the Netherlands.
DEZIMA PHARMA
Industry:
Biotechnology Therapeutics
Founded:
2012-01-01
Address:
Naarden, Noord-Holland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.dezimapharma.com
Total Employee:
10001+
Status:
Closed
Contact:
+31 35 699 3000
Email Addresses:
[email protected]
Total Funding:
14.2 M EUR
Technology used in webpage:
SPF Google Font API PHP CenturyLink Savvis
Founder
Investors List
BioGeneration Ventures
BioGeneration Ventures investment in Venture Round - Dezima Pharma
Forbion Capital Partners
Forbion Capital Partners investment in Venture Round - Dezima Pharma
New Science Ventures
New Science Ventures investment in Venture Round - Dezima Pharma
Official Site Inspections
http://www.dezimapharma.com
- Host name: 63.128.150.233
- IP address: 63.128.150.233
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Dezima Pharma"
Dezima Pharma - Crunchbase Company Profile
Organization. Dezima Pharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Dezima Pharma B.V. develops โฆSee details»
Amgen To Acquire Privately-Held Dezima Pharma
Dezima Pharma was founded in 2012 by John Kastelein, professor of medicine at the Department of Vascular Medicine at the Academic Medical Center of the University of Amsterdam, The Netherlands, and financed by Forbion Capital โฆSee details»
Dezima Pharma - PitchBook
Dezima Pharma General Information Description. Developer of novel drugs intended to treat dyslipidemic patients suffering from cardiovascular disease. The company develops a cholesteryl ester transfer protein inhibitor that acts as a โฆSee details»
Dezima Pharma | BioGeneration Ventures
Dezima Pharma. Dezima Pharma develops a best in class CETP inibitor for the treatment of cardiovascular disease. Dezima Pharma was acquired by Amgen in 2015. Currently New Amsterdam Pharma is developing the Dezima assets. โฆSee details»
Dezima Pharma - Products, Competitors, Financials, Employees ...
Dezima Pharma was founded in 2012. Where is Dezima Pharma's headquarters? Dezima Pharma's headquarters is located at Gooimeer 2 - 35, Naarden. What is Dezima Pharma's โฆSee details»
Dezima Pharma - Company Profile - Tracxn
Oct 31, 2024 Dezima Pharma ranks 50th among 231 active competitors. 80 of its competitors are funded while 67 have exited. Overall, Dezima Pharma and its competitors have raised โฆSee details»
Dezima Pharma BV - Company Profile and News - Bloomberg โฆ
Company profile page for Dezima Pharma BV including stock price, company news, executives, board members, and contact informationSee details»
Dezima Pharma - VentureRadar
Dezima Pharma develops novel compounds to treat cardiovascular disease related to dyslipidemia. Its lead compound is a potentially best-in-class CETP inhibitor currently in mid โฆSee details»
Dezima Pharma - Owler
Dezima Pharmaโs Profile, Revenue and Employees. Dezima Pharma is engaged in the development of novel drugs to treat cardiovascular disease related to dyslipidemia. Dezima โฆSee details»
Dezima Pharma - Crunchbase Company Profile & Funding
Dezima Pharma develops protein-based compounds for treatment of cardiovascular disease related to dyslipidemia.See details»
Amgen to acquire biotechnology company Dezima
Sep 17, 2015 Following the completion of the transaction, Dezima Pharma, which originally licensed rights to TA-8995 from Mitsubishi Tanabe Pharma Corporation (MTPC), will become โฆSee details»
Dezima Pharma | Insights
Oct 26, 2017 Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
Amgen snaps up Dutch biotech Dezima for $1.55 billion
Sep 16, 2015 Dezima Pharma, which is located in the Netherlands, develops treatments for dyslipidemia. Dezima was founded three years ago and is headquartered in Naarden. The โฆSee details»
Amgen expands cardiovascular portfolio with Dezima acquisition
The US biopharmaceutical firm Amgen is enlarging its cardiovascular treatment portfolio through a $300 million (£191 million) acquisition of the Netherlands-based biotechnology company ...See details»
Amgen To Acquire Privately-Held Dezima Pharma | Amgen Inc.
Dezima Pharma was founded in 2012 by John Kastelein, professor of medicine at the Department of Vascular Medicine at the Academic Medical Center of the University of Amsterdam, The โฆSee details»
NewAmsterdam Pharma - VentureRadar
In April 2020, NewAmsterdam acquired Dezima Pharma from Amgen, including all rights for obicetrapib (TA-8995), a novel, selective, cholesteryl ester transfer protein (CETP) inhibitor. โฆSee details»
Amgen to pay $300 million in cash for Dezima Pharma
EFT Report, Bengaluru: Amgen Inc said it will buy biotechnology company Dezima Pharma B.V., adding another cholesterol drug to its expanding portfolio of treatments for cardiovascular โฆSee details»
Ex-Dezima executives scoop โฌ25M for midphase NASH trial
Dec 12, 2017 NorthSea Therapeutics has raised โฌ25 million ($29 million) to put a NASH drug through phase 2b. The round reunites some of the executives and investors who helped โฆSee details»
NewAmsterdam Pharma Doses First Patient in Phase 3 โฆ
Jan 4, 2022 In April 2020, NewAmsterdam acquired Dezima Pharma from Amgen, including all rights for obicetrapib (formerly AMG 899, now TA-8995) a selective cholesteryl ester transfer โฆSee details»
ๅฎ่ฟ30ๅคไบฟ็พๅ ่พพๆ2้กนไบคๆ๏ผๅ ๅผบๅ ถ็ ๅ็ฎก็บฟ - PhIRDA
Sep 22, 2015 ๅฎ่ฟๆถ่ดญ่ทๅ ฐ็็ฉๆๆฏๅ ฌๅธ Dezima Pharma ๏ผไธบๅ ถๅฟ่ก็ฎก็พ็ ็ ๅ็ฎก็บฟๆทปๅ ็ ็ ๏ผๅๆถไนๅจ็ซญๅไธ็็ๅ ็ซ็ๆณๅ ฌๅธ Xencor ๅจ่ฟ็คไธ็็่ฏ็ฉไธ่พพๆๅไฝๆๅ๏ผๅ ฑๅๅผๅๅ โฆSee details»